Glyco_CARTs exhibit selective reactivity towards Tn glycosylated epitopes that are abundantly expressed in cancer cells while showing no reactivity towards normal healthy tissue. This holds significant importance in the context of solid tumors. Fantastic work by Asted and colleagues demonstrates that 4C8 CAR T cells, which target the cancer-associated O-glucan CD44v, selectively eliminated Tn-expressing cancer cells both in vivo and in vitro.
glyco-CARTs for the treatment of solid cancers! See our new publication, where we use a mAb with exquisite cancer-specificity to target cancer-associated O-glycans on CD44v6 expressed on multiple solid tumors. Safety was demonstrated with 3D organotypic mixed skin cancer models. Great collaboration with all involved at GO Therapeutics, the University of Copenhagen, and our collaborator Avery Posey and his team at UPenn https://lnkd.in/eq9Gud8K